Neuroendocrine Tumors Clinical Practice Guidelines
Neuroendocrine tumors are relatively rare. An estimated 25,690 new cases of thyroid cancer will be diagnosed in the United States in 2005, accounting for approximately 1% of all malignancies. Neuroendocrine tumors can be broadly subdivided into tumors that are benign or malignant, functional (i.e., producing a syndrome of hormonal excess) or nonfunctional. The management of neuroendocrine tumors with surgical, medical, or radiation therapies is determined by the specific endocrine glands involved, aggressiveness and stage of the tumor, hormonal concentrations detected, and specific patient needs. These guidelines have been designed to address scenarios presented by 80% of patients and to avoid scenarios relevant to less than 5% of patients.
For the most recent version of the guidelines, please visit NCCN.org
The Stanford Cancer Center is an international leader in cancer research and patient care. The mission of the Stanford Clinical Cancer Program is to provide comprehensive care through multidisciplinary collaboration and integrated services; advance cancer therapies through clinical research; and train future leaders in the treatment of patients with cancer. The collaborative approach to cancer research and treatment is a hallmark of this program.
One hundred and sixty faculty members participate in cancer care and clinical research with over 250 active clinical trials. Stanford researchers and physicians have led the way in developing many of the current state-of-the-art radiology, antibody, and biologic therapies that are used to treat cancers. The Cancer Center also encompasses basic population-based research into the causes and consequences of cancer and supports 16 interdisciplinary disease-related programs.
Steven A. Leibel, MD, is the Medical Director of the Stanford Cancer Center and a professor of Radiation Oncology. He joined Stanford in 2004. Irv Weissman, MD (not pictured), is the Director, and Beverly Mitchell, MD (not pictured), is the Deputy Director of the Stanford University Comprehensive Cancer Center.
© 2019-2023 National Comprehensive Cancer Network